{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:21:31Z","timestamp":1789147291737,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005713","name":"Technische Universit\u00e4t M\u00fcnchen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Triple-negative breast cancer (TNBC) comprises several molecularly distinct subtypes. The luminal androgen receptor (LAR) subtype is characterized by AR expression, displays luminal-like gene signatures, and often co-expresses FOXA1 and GCDFP-15, but its immunohistochemical identification remains challenging. Through transcriptomic analyses of GEO datasets, we identified MUCL1 as a candidate marker and validated its protein expression in a retrospective cohort of 106 TNBCs. MUCL1 was expressed in 25% of cases in our cohort, enriched in apocrine and lobular carcinomas, and strongly correlated with AR, FOXA1, and GCDFP-15. MUCL1-positive tumors occurred in older patients, were larger, and showed lower grade and proliferation, features which are known to be associated with the LAR subtype. Importantly, MUCL1\u2013\/AR+\u2009tumors resembled MUCL1\u2013\/AR\u2013 rather than MUCL1-positive cases, suggesting that AR expression alone may not fully capture the underlying biology of this subgroup, while MUCL1 expression was associated with a more coherent clinicopathological phenotype aligned with LAR-associated features. Transcriptomic enrichment of hormone response and metabolic pathways in MUCL1-high tumors supports this association. Evidence linking both LAR and MUCL1 to reduced chemotherapy sensitivity highlights the clinical relevance of MUCL1.<\/jats:p>","DOI":"10.1186\/s13058-026-02283-y","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:26:30Z","timestamp":1776266790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MUCL1 in triple-negative breast cancer: a novel marker associated with the luminal androgen receptor subtype"],"prefix":"10.1186","volume":"28","author":[{"given":"Franz-Leonard","family":"Klaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Kitzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Mogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Muckenhuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2283_CR1","doi-asserted-by":"publisher","first-page":"1405491","DOI":"10.3389\/fonc.2024.1405491","volume":"14","author":"N Xiong","year":"2024","unstructured":"Xiong N, Wu H, Yu Z. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies. Front Oncol. 2024;14:1405491.","journal-title":"Front Oncol"},{"key":"2283_CR2","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429\u201334.","journal-title":"Clin Cancer Res"},{"key":"2283_CR3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.22618","volume":"109","author":"KR Bauer","year":"2007","unstructured":"Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)\u2010negative, progesterone receptor (PR)\u2010negative, and HER2\u2010negative invasive breast cancer, the so\u2010called triple\u2010negative phenotype: a population\u2010based study from the California cancer Registry. Cancer. 2007;109:1721\u20138.","journal-title":"Cancer"},{"key":"2283_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"2283_CR5","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u201367.","journal-title":"J Clin Invest"},{"key":"2283_CR6","doi-asserted-by":"publisher","first-page":"zcac018","DOI":"10.1093\/narcan\/zcac018","volume":"4","author":"KJ Thompson","year":"2022","unstructured":"Thompson KJ, et al. Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. NAR Cancer. 2022;4:zcac018.","journal-title":"NAR Cancer"},{"key":"2283_CR7","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1038\/s41598-025-87403-y","volume":"15","author":"H Nishida","year":"2025","unstructured":"Nishida H, Kato A, Kaimori R, Kawamura K, Daa T. Relationship between androgen receptor and androgen receptor-related protein expression in breast cancers focusing on morphologically identified carcinoma with apocrine differentiation. Sci Rep. 2025;15:2892.","journal-title":"Sci Rep"},{"key":"2283_CR8","doi-asserted-by":"publisher","first-page":"11468","DOI":"10.3390\/ijms231911468","volume":"23","author":"M Long","year":"2022","unstructured":"Long M, et al. AR expression correlates with distinctive clinicopathological and genomic features in breast cancer regardless of ESR1 expression status. Int J Mol Sci. 2022;23:11468.","journal-title":"Int J Mol Sci"},{"key":"2283_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ctrv.2018.06.005","volume":"68","author":"L Gerratana","year":"2018","unstructured":"Gerratana L, et al. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev. 2018;68:102\u201310.","journal-title":"Cancer Treat Rev"},{"key":"2283_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41416-018-0142-6","volume":"119","author":"S Guiu","year":"2018","unstructured":"Guiu S, et al. Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. Br J Cancer. 2018;119:76\u20139.","journal-title":"Br J Cancer"},{"key":"2283_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/modpathol.2011.54","volume":"24","author":"LC Collins","year":"2011","unstructured":"Collins LC, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses\u2019 Health Study. Mod Pathol. 2011;24:924\u201331.","journal-title":"Mod Pathol"},{"key":"2283_CR12","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1038\/emboj.2011.216","volume":"30","author":"JLL Robinson","year":"2011","unstructured":"Robinson JLL, et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 2011;30:3019\u201327.","journal-title":"EMBO J"},{"key":"2283_CR13","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/1471-2407-14-546","volume":"14","author":"S Darb-Esfahani","year":"2014","unstructured":"Darb-Esfahani S, et al. Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. BMC Cancer. 2014;14:546.","journal-title":"BMC Cancer"},{"key":"2283_CR14","first-page":"135","volume":"4","author":"S Loos","year":"1999","unstructured":"Loos S, Schulz KD, Hackenberg R. Regulation of GCDFP-15 expression in human mammary cancer cells. Int J Mol Med. 1999;4:135\u201375.","journal-title":"Int J Mol Med"},{"key":"2283_CR15","doi-asserted-by":"publisher","first-page":"102993","DOI":"10.1016\/j.esmoop.2024.102993","volume":"9","author":"H Hu","year":"2024","unstructured":"Hu H, et al. Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin. ESMO Open. 2024;9:102993.","journal-title":"ESMO Open"},{"key":"2283_CR16","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/j.ejca.2008.04.020","volume":"44","author":"HO Habashy","year":"2008","unstructured":"Habashy HO, et al. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer. 2008;44:1541\u201351.","journal-title":"Eur J Cancer"},{"key":"2283_CR17","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1038\/onc.2015.487","volume":"35","author":"SJ Conley","year":"2016","unstructured":"Conley SJ, et al. HER2 drives Mucin-like 1 to control proliferation in breast cancer cells. Oncogene. 2016;35:4225\u201334.","journal-title":"Oncogene"},{"key":"2283_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s13353-024-00876-x","volume":"66","author":"S Supplitt","year":"2025","unstructured":"Supplitt S, et al. The analysis of transcriptomic signature of TNBC\u2014searching for the potential RNA-based predictive biomarkers to determine the chemotherapy sensitivity. J Appl Genet. 2025;66:171\u201382.","journal-title":"J Appl Genet"},{"key":"2283_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3892\/or.2020.7640","volume":"44","author":"Q Li","year":"2020","unstructured":"Li Q, et al. Small breast epithelial mucin promotes the invasion and metastasis of breast cancer cells via promoting epithelial-to-mesenchymal transition. Oncol Rep. 2020;44:509\u201318.","journal-title":"Oncol Rep"},{"key":"2283_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2559.2007.02955.x","volume":"52","author":"GP Skliris","year":"2008","unstructured":"Skliris GP, et al. Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers. Histopathology. 2008;52:355\u201369.","journal-title":"Histopathology"},{"key":"2283_CR21","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.1016\/j.clbc.2020.01.002","volume":"20","author":"M Xu","year":"2020","unstructured":"Xu M, et al. Prognostic significance of Androgen Receptor expression in Triple Negative Breast Cancer: a systematic review and meta-analysis. Clin Breast Cancer. 2020;20:e385\u201396.","journal-title":"Clin Breast Cancer"},{"key":"2283_CR22","doi-asserted-by":"publisher","first-page":"e0157368","DOI":"10.1371\/journal.pone.0157368","volume":"11","author":"BD Lehmann","year":"2016","unstructured":"Lehmann BD, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE. 2016;11:e0157368.","journal-title":"PLoS ONE"},{"key":"2283_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s00428-021-03185-4","volume":"480","author":"CM Quinn","year":"2022","unstructured":"Quinn CM, D\u2019Arcy C, Wells C. Apocrine lesions of the breast. Virchows Arch. 2022;480:177\u201389.","journal-title":"Virchows Arch"},{"key":"2283_CR24","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/s41379-021-00742-9","volume":"34","author":"A Bergeron","year":"2021","unstructured":"Bergeron A, et al. Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. Mod Pathol. 2021;34:1282\u201396.","journal-title":"Mod Pathol"},{"key":"2283_CR25","doi-asserted-by":"publisher","first-page":"e240316","DOI":"10.1530\/ERC-24-0316","volume":"32","author":"N Rangel","year":"2025","unstructured":"Rangel N, et al. Surrogate molecular classification of LAR breast cancer in routine workflow. Endocr Relat Cancer. 2025;32:e240316.","journal-title":"Endocr Relat Cancer"},{"key":"2283_CR26","doi-asserted-by":"publisher","first-page":"e0197827","DOI":"10.1371\/journal.pone.0197827","volume":"13","author":"K Astvatsaturyan","year":"2018","unstructured":"Astvatsaturyan K, Yue Y, Walts AE, Bose S. Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features. PLoS ONE. 2018;13:e0197827.","journal-title":"PLoS ONE"},{"key":"2283_CR27","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1158\/1078-0432.CCR-18-0585","volume":"24","author":"P Sharma","year":"2018","unstructured":"Sharma P, et al. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clin Cancer Res. 2018;24:5820\u20139.","journal-title":"Clin Cancer Res"},{"key":"2283_CR28","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.1038\/sj.onc.1208561","volume":"24","author":"P Farmer","year":"2005","unstructured":"Farmer P, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660\u201371.","journal-title":"Oncogene"},{"key":"2283_CR29","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1038\/sj.onc.1209415","volume":"25","author":"AS Doane","year":"2006","unstructured":"Doane AS, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25:3994\u20134008.","journal-title":"Oncogene"},{"key":"2283_CR30","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1200\/JCO.19.00693","volume":"37","author":"P Sharma","year":"2019","unstructured":"Sharma P, et al. Validation of the DNA damage immune response signature in patients with triple-negative breast cancer from the SWOG 9313c trial. J Clin Oncol. 2019;37:3484\u201392.","journal-title":"J Clin Oncol"},{"key":"2283_CR31","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2022.5312","author":"M Abdulla","year":"2022","unstructured":"Abdulla M, et al. Targeting MUCL1 protein inhibits cell proliferation and EMT by deregulating \u03b2\u2011catenin and increases irinotecan sensitivity in colorectal cancer. Int J Oncol. 2022. https:\/\/doi.org\/10.3892\/ijo.2022.5312.","journal-title":"Int J Oncol"},{"key":"2283_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1746-1596-8-71","volume":"8","author":"L Liu","year":"2013","unstructured":"Liu L, et al. Small breast epithelial mucin tumor tissue expression is associated with increased risk of recurrence and death in triple-negative breast cancer patients. Diagn Pathol. 2013;8:71.","journal-title":"Diagn Pathol"},{"key":"2283_CR33","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1038\/s41467-025-58158-x","volume":"16","author":"M Aine","year":"2025","unstructured":"Aine M, et al. The DNA methylation landscape of primary triple-negative breast cancer. Nat Commun. 2025;16:3041.","journal-title":"Nat Commun"},{"key":"2283_CR34","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.2217\/fon.15.102","volume":"11","author":"S Guiu","year":"2015","unstructured":"Guiu S, et al. Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial. Future Oncol. 2015;11:2283\u201397.","journal-title":"Future Oncol"},{"key":"2283_CR35","doi-asserted-by":"publisher","first-page":"6276","DOI":"10.1038\/s41467-021-26502-6","volume":"12","author":"BD Lehmann","year":"2021","unstructured":"Lehmann BD, et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun. 2021;12:6276.","journal-title":"Nat Commun"},{"key":"2283_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10585-010-9323-2","volume":"27","author":"Z-Z Liu","year":"2010","unstructured":"Liu Z-Z, Xie X-D, Qu S-X, Zheng Z-D, Wang Y-K. Small breast epithelial mucin (SBEM) has the potential to be a marker for predicting hematogenous micrometastasis and response to neoadjuvant chemotherapy in breast cancer. Clin Exp Metastasis. 2010;27:251\u20139.","journal-title":"Clin Exp Metastasis"},{"key":"2283_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13058-020-01369-5","volume":"22","author":"S Bhattarai","year":"2020","unstructured":"Bhattarai S, Saini G, Gogineni K, Aneja R. Quadruple-negative breast cancer: novel implications for a new disease. Breast Cancer Res. 2020;22:127.","journal-title":"Breast Cancer Res"},{"key":"2283_CR38","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.7150\/thno.36182","volume":"10","author":"F Coussy","year":"2020","unstructured":"Coussy F, et al. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Theranostics. 2020;10:1531\u201343.","journal-title":"Theranostics"},{"key":"2283_CR39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.humpath.2018.06.007","volume":"80","author":"A Harbhajanka","year":"2018","unstructured":"Harbhajanka A, et al. Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma. Hum Pathol. 2018;80:163\u20139.","journal-title":"Hum Pathol"},{"key":"2283_CR40","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"Y-Z Jiang","year":"2019","unstructured":"Jiang Y-Z, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019;35:428-440.e5.","journal-title":"Cancer Cell"},{"key":"2283_CR41","doi-asserted-by":"publisher","first-page":"11278","DOI":"10.1038\/s41598-024-61640-z","volume":"14","author":"M Lee","year":"2024","unstructured":"Lee M, et al. Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification. Sci Rep. 2024;14:11278.","journal-title":"Sci Rep"},{"key":"2283_CR42","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, et al. Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications. Nat Commun. 2024;15:10232.","journal-title":"Nat Commun"},{"key":"2283_CR43","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1159\/000519255","volume":"16","author":"C Hartung","year":"2021","unstructured":"Hartung C, et al. Identifying high-risk triple-negative breast cancer patients by molecular subtyping. Breast Care. 2021;16:637\u201347.","journal-title":"Breast Care"},{"key":"2283_CR44","doi-asserted-by":"publisher","first-page":"100125","DOI":"10.1016\/j.modpat.2023.100125","volume":"36","author":"CJ Schwartz","year":"2023","unstructured":"Schwartz CJ, et al. Triple-negative apocrine carcinomas: toward a unified group with shared molecular features and clinical behavior. Mod Pathol. 2023;36:100125.","journal-title":"Mod Pathol"},{"key":"2283_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41523-022-00415-z","volume":"8","author":"P Srivastava","year":"2022","unstructured":"Srivastava P, et al. Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers. Npj Breast Cancer. 2022;8:51.","journal-title":"Npj Breast Cancer"},{"key":"2283_CR46","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00124","author":"RK Basho","year":"2024","unstructured":"Basho RK, et al. Comprehensive analysis identifies variability in PI3K pathway alterations in triple-negative breast cancer subtypes. JCO Precis Oncol. 2024. https:\/\/doi.org\/10.1200\/PO.23.00124.","journal-title":"JCO Precis Oncol"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02283-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02283-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02283-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T13:03:07Z","timestamp":1776344587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02283-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2283"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02283-y","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the ethics committee of the Faculty of Medicine at Klinikum rechts der Isar, Technical University of Munich (2024-487-S-CB).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}